Skip to main content
Premium Trial:

Request an Annual Quote

Peter Dansky, Kip Miller, Nicolas Barthelemy, David Hoffmeister, Bernd Brust, Peter Leddy, Mark O’Donnell, John Cottingham, Paul Grossman, Joe Beery, Brian Pollock, Mark Smedley

Premium
Invitrogen and Applied Biosystems have named the executives that will lead the four divisions of the merged company. The molecular biology systems division will be led by Peter Dansky, who currently serves as leader of ABI’s molecular and cell biology functional analysis division. It will include the workflows of both firms related to molecular biology, such as gene expression, genotyping, gene regulation, and proteomics.
 
The genetic systems division will be led by Kip Miller, who currently serves as leader of Invitrogen’s Biodiscovery division. It will include ABI’s capillary electrophoresis and SOLiD sequencing systems, as well as Invitrogen’s third-generation sequencing development program.
 
The cell systems division will be led by Nicolas Barthelemy, who currently heads Invitrogen’s cell systems division. It will include Invitrogen’s current cell systems operations and ABI’s Poros and Tropix business lines.
 
The mass spectrometry division will be led by Laura Lauman, who currently leads ABI’s proteomics and small molecule division, and will house ABI’s mass spec business.
 
In addition, David Hoffmeister, currently Invitrogen’s CFO, will assume the same position at the new company; Bernd Brust, head of invitrogen’s global sales and marketing, will head global commercial operations; Peter Leddy, head of Invitrogen’s human resources, will become head of global human resources; Mark O’Donnell, now head of ABI's global services and supply chain, will lead global operations and services; John Cottingham, general counsel for Invitrogen, will become chief legal officer; Paul Grossman, Invitrogen’s lead for strategy and corporate development, will assume the same title; Joe Beery will take on the same title he currently holds at Invitrogen, head of information technology; Brian Pollock, CSO of Invitrogen, will be head of global research and development; and Mark Smedley will continue as full-time integration leader and head of the Integration Management Office. He has been directing the integration efforts.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.